top of page

Time to bring personalised cell therapies in care of chronic wounds

Our Services

Therapy for Chronic Wounds

Healiva® is a patient-centric Swiss Biotech company, delivering personalised therapy to improve patient’s quality of life. We use a multi-pronged approach to address patient needs by combining cell therapies, enzyme technology and medical devices to deliver tailored solutions for chronic wounds. We are the first Biotech to offer multiple end-to-end, intuitive wound care products that can be personalised whilst remaining affordable.

Mission

Our mission is to commercialize a portfolio of innovative, personalised and affordable therapies for chronic and acute wounds and targeting key pain points in the patient care pathway. There remains a major gap in the current treatment paradigm. No permanent therapy for non-healing wounds currently exists.

Test Tubes

Wounds: A sizeable problem

156M

Chronic wound patients worldwide 

2-3% of the elderly have painful Venous/Arterial Leg Ulcers


25% of diabetics have disabling diabetic foot ulcers

9.7M

Venous leg ulcers and 

10M

Diabetic Foot ulcers patients

€21.7B

in 2022 according to PitchBook Data

8%

CAGR by 2026

A group of people talking with tablet PC in hand

Pipeline Products

Healiva Technological Breakthroughs 

Healiva products

Indication

Pre-clinical discovery

Pre-clinical development

Ph I/IIa

Ph IIb

Ph III

Market phase

AQUAtryp

Acute & chronic wounds

Healiva 004

VLUs & DFUs / chronic wounds

Healiva 002

VLUs & DFUs / chronic wounds

Epidex

Severe VLUs / chronic wounds

Work with
us

Fill the form :
bottom of page